Citation Impact
Citing Papers
In VivoEvaluation of pH-Sensitive Polymer-Based Immunoliposomes Targeting the CD33 Antigen
2010
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
2013
Advances in immunotherapy for melanoma
2016
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Intracellular Delivery System for Antibody–Peptide Drug Conjugates
2015 StandoutNobel
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
2015
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
2015
The application of nanotechnology in immune checkpoint blockade for cancer treatment
2018
Cancer Stem Cells
2006
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia
2002
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
2003
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
2003
Combination cancer immunotherapy and new immunomodulatory targets
2015
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
2015
The biology and management of non-small cell lung cancer
2018 StandoutNature
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
2005
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
2014
Cancer Statistics, 2006
2006 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Immuno-Oncology: Emerging Targets and Combination Therapies
2018
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy
2018
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Potent antibody drug conjugates for cancer therapy
2009
Lung cancer: current therapies and new targeted treatments
2016 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Immune checkpoint inhibitors in melanoma
2021
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
2015
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
A timeline of tumour-associated macrophage biology
2023
Identification and expansion of human colon-cancer-initiating cells
2006 StandoutNature
Immune checkpoint modulation: Rational design of combination strategies
2015
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia
2005
Next generation of immune checkpoint therapy in cancer: new developments and challenges
2018
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activity
2013
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers
2012
IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
2014
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers
2002
Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease
2012
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
Targeting the Bcl-2 family for cancer therapy
2012
Targeting lactate metabolism for cancer therapeutics
2013
Renal cell carcinoma
2017 Standout
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
2015
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Arming antibodies: prospects and challenges for immunoconjugates
2005
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
2018
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity
2003
Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies
2005
Crystal Structures of Protein-Bound Cyclic Peptides
2019
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
2013
Acute Myeloid Leukemia
2015 Standout
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Coinhibitory Pathways in Immunotherapy for Cancer
2016
Immunotherapy for Colorectal Cancer
2017
Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cells
2003
Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies
2002
Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis
2015 StandoutNobel
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Discovery of IDO1 Inhibitors: From Bench to Bedside
2017
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
2017
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The Janus-Faced Nature of Ido1 in Infectious Diseases: Challenges and Therapeutic Opportunities
2015
Chimeric Antigen Receptor Therapy
2018 Standout
Antibody therapy for acute myeloid leukaemia
2013
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
2003
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
Aryl-fluorosulfate-based Lysine Covalent Pan-Inhibitors of Apoptosis Protein (IAP) Antagonists with Cellular Efficacy
2019
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
2017
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
A phase I study of indoximod in patients with advanced malignancies
2016
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
2004
Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
2003
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromes
2003
Genetics and biology of pancreatic ductal adenocarcinoma
2016
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis
2018 StandoutNobel
Works of Lance Leopold being referenced
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
2015
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
2010
Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse
2002
Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia
2002
Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
2010
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
2017
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
2005
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
2017
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
2014
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
2009
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
2013
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
2003
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
2018
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
2001
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
2008
Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
2015
Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea
2013
Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients.
2012
A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment
2011